| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms SD Gore, S Baylin, E Sugar, H Carraway, CB Miller, M Carducci, M Grever, ... Cancer research 66 (12), 6361-6369, 2006 | 596 | 2006 |
| Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide SA Grossman, X Ye, G Lesser, A Sloan, H Carraway, S Desideri, ... Clinical cancer research 17 (16), 5473-5480, 2011 | 514 | 2011 |
| MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation ME Figueroa, L Skrabanek, Y Li, A Jiemjit, TE Fandy, E Paietta, ... Blood, The Journal of the American Society of Hematology 114 (16), 3448-3458, 2009 | 402 | 2009 |
| Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology PL Greenberg, RM Stone, A Al-Kali, SK Barta, R Bejar, JM Bennett, ... Journal of the National Comprehensive Cancer Network 15 (1), 60-87, 2017 | 326 | 2017 |
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies TE Fandy, JG Herman, P Kerns, A Jiemjit, EA Sugar, SH Choi, AS Yang, ... Blood, The Journal of the American Society of Hematology 114 (13), 2764-2773, 2009 | 307 | 2009 |
| Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients AE Frankel, JH Woo, C Ahn, N Pemmaraju, BC Medeiros, HE Carraway, ... Blood, The Journal of the American Society of Hematology 124 (3), 385-392, 2014 | 239 | 2014 |
| Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α F Vesuna, A Lisok, B Kimble, J Domek, Y Kato, P van der Groep, ... Oncogene 31 (27), 3223-3234, 2012 | 196 | 2012 |
| Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes A Nazha, M Narkhede, T Radivoyevitch, DJ Seastone, BJ Patel, AT Gerds, ... Leukemia 30 (11), 2214-2220, 2016 | 172 | 2016 |
| Emerging therapies for acute myeloid leukemia C Saygin, HE Carraway Journal of hematology & oncology 10, 1-14, 2017 | 152 | 2017 |
| MS-qFRET: a quantum dot-based method for analysis of DNA methylation VJ Bailey, H Easwaran, Y Zhang, E Griffiths, SA Belinsky, JG Herman, ... Genome research 19 (8), 1455-1461, 2009 | 152 | 2009 |
| New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists H Carraway, M Hidalgo Breast cancer research 6, 1-6, 2004 | 140 | 2004 |
| Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer RJ Molenaar, S Sidana, T Radivoyevitch, AS Advani, AT Gerds, ... Journal of clinical oncology 36 (18), 1831-1839, 2018 | 139 | 2018 |
| Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias JE Karp, BM Thomas, JM Greer, C Sorge, SD Gore, KW Pratz, BD Smith, ... Clinical Cancer Research 18 (24), 6723-6731, 2012 | 135 | 2012 |
| HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation AM Zeidan, PM Forde, H Symons, A Chen, BD Smith, K Pratz, H Carraway, ... Biology of Blood and Marrow Transplantation 20 (3), 314-318, 2014 | 127 | 2014 |
| Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms DP Steensma, M Wermke, VM Klimek, PL Greenberg, P Font, ... Leukemia 35 (12), 3542-3550, 2021 | 115 | 2021 |
| Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation EA Griffiths, SD Gore, C Hooker, MA McDevitt, JE Karp, BD Smith, ... Leukemia & lymphoma 51 (9), 1711-1719, 2010 | 114 | 2010 |
| A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias JE Karp, RM Ricklis, K Balakrishnan, J Briel, J Greer, SD Gore, BD Smith, ... Blood, The Journal of the American Society of Hematology 110 (6), 1762-1769, 2007 | 111 | 2007 |
| Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates X Gu, Q Ebrahem, RZ Mahfouz, M Hasipek, F Enane, T Radivoyevitch, ... The Journal of clinical investigation 128 (10), 4260-4279, 2018 | 110 | 2018 |
| Tamoxifen-stimulated growth of breast cancer due to p21 loss AM Abukhdeir, MI Vitolo, P Argani, AM De Marzo, B Karakas, H Konishi, ... Proceedings of the National Academy of Sciences 105 (1), 288-293, 2008 | 107 | 2008 |
| Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms RJ Molenaar, S Thota, Y Nagata, B Patel, M Clemente, B Przychodzen, ... Leukemia 29 (11), 2134-2142, 2015 | 105 | 2015 |
